Search Results - "Navalón, C Iniesta"

Identification of potential clinically significant drug interactions in HIV‐infected patients: a comprehensive therapeutic approach by Iniesta‐Navalón, C, Franco‐Miguel, JJ, Gascón‐Cánovas, JJ, Rentero‐Redondo, L

“…Objectives The aim of the study was to determine the prevalence of potential clinically significant drug interactions (CSDIs) in HIV‐positive individuals and…”
Get full text

5PSQ-156 Reasons for secukinumab treatment discontinuation by Pastor Mondéjar, C, Iniesta Navalón, C, Martinez Soto, A, Ortiz Fernandez, P, Ferandez-Villacañas Ferandez, P, Rentero Redondo, L, Caballero Requejo, C, Garcia Coronel, M, Salar Valverde, I, Urbieta Sanz, E

“…Background and importanceSecukinumab is an immunoglobulin G1 monoclonal antibody that selectively binds to interleukin 17A and inhibits its interaction with…”
Get full text

4CPS-326 Adalimumab’s persistence in rheumatological diseases by Pastor Mondéjar, C, Iniesta Navalón, C, Salar Valverde, I, Martínez Soto, AM, Ortiz Fernández, P, Gil Candel, M, Rentero Redondo, L, Onteniente Candela, M, García Coronel, M, Caballero Requejo, MDC, Urbieta Sanz, E

“…Background and importanceAdalimumab is a human monoclonal recombinant antibody whose mechanism of action is mediated by binding specifically to tumour necrosis…”
Get full text

5PSQ-179 Reason for discontinuation of biological drug treatment in rheumatoid arthritis by Pastor Mondéjar, C, Iniesta Navalón, C, Salar Valverde, I, Martínez Soto, AM, Ortíz Fernández, P, Gil Candel, M, García Coronel, M, Quesada Asencio, A, Onteniente Candela, M, Caballero Requejo, MDC, Urbieta Sanz, E

“…Background and importanceRheumatoid arthritis is a chronic, autoimmune disease, with unknown aetiology, characterised by chronic inflammation of synovial…”
Get full text

5PSQ-176 Discontinuation of etanercept due to adverse events in patients with rheumatic diseases by Pastor Mondéjar, C, Iniesta Navalón, C, Salar Valverde, I, Martínez Soto, AM, Ortíz Fernández, P, Gil Candel, M, Onteniente Candela, M, Quesada Asencio, A, Caballero Requejo, MDC, Rentero Redondo, L, Urbieta Sanz, E

“…Background and importanceEtanercept is a fusion protein composed of the p75 receptor of tumour necrosis factor (TNF) and the Fc portion of human…”
Get full text

5PSQ-083 Study of the prevalence of immunogenicity in patients treated with anti-tumour necrosis factor monoclonal antibodies by Candel, M Gil, Navalón, C Iniesta, Candela, M Onteniente, Redondo, L Rentero, Requejo, C Caballero, Valverde, N Salar, Muñoz, C Gallego

“…BackgroundThe loss of response in patients treated with anti-TNFα monoclonal antibodies is relatively frequent. One of the reasons is the development of…”
Get full text

4CPS-144 Effectiveness and safety of induction therapy with vedolizumab in patients with intestinal inflammatory disease by Muñoz, C Gallego, Candel, M Gil, Navalón, C Iniesta, Requejo, C Caballero, Candela, M Onteniente, Valverde, I Salar

“…BackgroundVedolizumab is a therapeutic alternative indicated in patients with moderate-severe inflammatory bowel disease (IBD) (ulcerative colitis (UC) and…”
Get full text

5PSQ-128 Pharmacotherapeutic profile and risk of drug-related problems and drug interactions in HIV+ patients of a health area by Onteniente Candela, M, Salar Valverde, I, Gil Candel, M, Pastor Mondéjar, C, Iniesta Navalón, C, Caballero Requejo, C, García Coronel, M, Urbieta Sanz, E

“…BackgroundThe expected lifespan of HIV +patients has increased dramatically as a result of improved antiretroviral therapy (ART), with the consequent increase…”
Get full text

CP-209 Metabolic complications in patients with parenteral nutrition by Candela, Onteniente, Vivancos, Ferriz, Navalón, C Iniesta, Candel, M Gil, Requejo, C Caballero, Ruiz, A Trujillano, Sáez, C García-Molina, Redondo, L Rentero

“…BackgroundParenteral nutrition (PN) is an important part of medical management of patients with a non-functioning and/or non-accessible gastrointestinal tract,…”
Get full text

PP-030 Effectiveness of a topical sirolimus formulation in patients with tuberous sclerosis by Ruiz, A Trujillano, Gómez, A López, Navalón, C Iniesta, Andreo, A Ramírez, Candela, M Onteniente, Requejo, C Caballero, Candel, M Gil, Rodríguez-Hermida, F Artime

“…BackgroundSirolimus is an immunosuppressant used with an off-label indication for angiofibromas in tuberous sclerosis.PurposeTo evaluate the effectiveness of…”
Get full text

Nutritional assessment at the time of hospital-admission: study initiation among different methodologies by Villamayor Blanco, L, Llimera Rausell, G, Jorge Vidal, V, González Pérez-Crespo, C, Iniesta Navalón, C, Mira Sirvent, M C, Martínez Penella, M, Rabell Iñigo, S

“…The elevated prevalence figures of hyponutrition in hospitalized patients--near 40%--is an issue of concern. This allows deducing that early identification of…”
Get full text

Inadequate prescription of drugs in the elderly by Iniesta Navalón, C, Urbieta Sanz, E, Gascón Cánovas, J J, Madrigal de Torres, M

Get more information

5PSQ-031 Evaluation of the safety and tolerance of the commercial presentation of cyclosporine 0.1% collyrium by Martínez Soto, AM, Garcia Coronel, M, Ortiz Fernandez, P, Marco Puig, JM, Pastor Mondéjar, C, Fernandez-Villacañas Fernandez, P, Rentero Redondo, L, Caballero Requejo, C, Iniesta Navalon, C, Salar Valverde, I, Urbieta Sanz, E

“…Background and importanceCyclosporine collyrium is used in the treatment of severe keratitis in adult patients with xerophthalmia who do not improve despite…”
Get full text

4CPS-222 Impact of the establishment of assisted electronic prescription on the improvement of the unit-dose drug dispensation system by Pastor Mondejar, C, Gil Candel, M, Salar Valverde, I, Onteniente Candela, M, Caballero Requejo, C, Iniesta Navalon, C, Urbieta Sanz, E

“…BackgroundThe aim of the unit-dose drug dispensation system (UDDDS) allows us to dispense the medication required for the patient for the following 24 hours…”
Get full text

3PC-051 Impact of ophthalmological preparations in the pharmacy service of a reference hospital by Salar Valverde, I, Manresa Ramon, N, Gil Candel, M, Onteniente Candela, M, Pastor Mondejar, C, Caballero Requejo, C, Iniesta Navalon, C, Garcia Coronel, M, Urbieta Sanz, E

“…BackgroundThere are many medicinal products that, although they have shown efficacy and safety in different ophthalmological indications, are not authorised or…”
Get full text

4CPS-153 Comparative analysis between originator and biosimilar infliximab according to trough levels in patients with inflammatory bowel disease by Gil Candel, M, Iniesta Navalon, C, Onteniente Candela, M, Salar Valverde, N, Pastor Mondejar, C, Rentero Redondo, L, Caballero Requejo, C, Urbieta Sanz, E

“…BackgroundThe introduction of biosimilar infliximab (IFX-B) has led to a decrease in the costs of patients with inflammatory bowel disease (IBD). The molecular…”
Get full text

P520 Association between ustekinumab trough levels and biomarkers in patients with Crohn’s disease by Nicolás de Prado, M I, Iniesta Navalón, C, Gomez Espin, R, Gil Candel, M, Serrano Díaz, L, Rentero Redondo, L, Martinez Crespo, J J

“…Abstract Background Ustekinumab (UTK) is a human immunoglobulin (Ig) G1 kappa monoclonal antibody approved in 2017 for the treatment of Crohn’s Disease (CD)…”
Get full text

Analysis of the drug interactions associated to domiciliary drug therapy in elderly hospitalized patients by Iniesta-Navalón, C, Urbieta-Sanz, E, Gascón-Cánovas, J J

“…To determine the prevalence of potentially relevant drug-drug interactions associated with chronic treatment of elderly patients over 64-years of age on…”
Get more information

P735 Immunogenicity differences between anti-TNF drugs by Gómez Espín, R M, Nicolás de Prado, I, Iniesta Navalón, C, Rentero Redondo, L, Gil Candel, M, Martínez Crespo, J J

“…Abstract Background The aim of this study was to determine the prevalence of immunogenicity in patients receiving anti-TNF drugs (infliximab and adalimumab) in…”
Get full text

CP-180 Quality of artificial nutrition support in an intensive care unit by Requejo, C Caballero, Navalon, C Iniesta, Ramon, N Manresa, Ruiz, A Trujillano, Candela, M Onteniente, Candel, M Gil, Alvarez, C Sanchez, Rodriguez-Hermida, F Artime

“…BackgroundArtificial nutrition is an essential component in the management of critically ill patients. These patients are at risk of developing malnutrition,…”
Get full text